Ozempic and Wegovy are among the 15 additional drugs selected for a list that will be negotiated for lower Medicare prices. Ten other drugs have already been selected for the Medicare list in an ...

WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and ...

Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today. From reproductive rights to climate change to Big Tech, The ...

Blockbuster diabetes drug Ozempic is on the list. That means the federal government and the pharmaceuticals industry are about to go head-to-head once again. The Centers for Medicare and Medicaid ...

Dec. 14, 2023. (AP Photo/Andrew Harnik, File) The injectable drug Ozempic is shown, July 1, 2023, in Houston. (AP Photo/David J. Phillip, File) A dosage of Wegovy, March 1, 2024 in Front Royal, Va.

FILE - President Joe Biden speaks about prescription drug costs at the National Institutes of Health in Bethesda, Md., Dec. 14, 2023. (AP Photo/Andrew Harnik, File) ...

Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden ...

Corbis / Corbis via Getty Images Medicare will negotiate prices for Ozempic and 14 other drugs in 2025, with prices taking effect in 2026. Negotiations could lower prices for Medicare ...

The White House on Friday said Novo Nordisk's weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

The selected drug list for the second cycle of negotiations is: Novo Nordisk's (NYSE:NVO) diabetes and weight loss drugs, Ozempic, Rybelsus, and Wegovy. Pfizer Inc.'s (NYSE:PFE) Ibrance for breast ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other medications, a cost-saving move that would take effect in 2027.